eZono

About eZono

Based in Jena, Germany, eZono AG operates as a specialized medical technology firm focused on point-of-care ultrasound systems. Founded in 2004 by Allan Dunbar and Andre Jaekel, the company aims to simplify the use of sonography for clinicians who are not ultrasound specialists, particularly in fields like regional anesthesia and emergency medicine. Allan Dunbar's background as a senior equity analyst for semiconductors and in R&D at ASM Lithography, combined with Andre Jaekel's experience in finance and investor relations at companies like Logitech and ABN AMRO, provided a foundation in both technology and business development.

The company's business model centers on the development, manufacturing, and sale of portable ultrasound devices and related software. Revenue is generated through the direct sale of these systems to healthcare providers and hospitals. The target market includes anesthesiologists, emergency care physicians, and other clinicians who perform procedural guidance at the point of care. By making ultrasound more accessible and easier to use, eZono helps improve patient safety, increase procedural success rates, and lower healthcare costs.

eZono's product line has evolved, starting with the eZono 3000 in 2010, followed by the flagship eZono 4000 in 2013, and the eZono 5000 in 2017. The core offering is a tablet-style ultrasound system featuring the proprietary eZGuide needle guidance technology. This technology uses magnetic detection to provide a real-time, on-screen display of the needle's trajectory and tip location, a significant advantage for complex procedures. A key feature is the system's compatibility with a wide range of standard needles, avoiding the need for expensive proprietary consumables. To shorten the learning curve for clinicians, the devices include an onboard educational software called Cue Cards, which offers step-by-step tutorials and 3D anatomical illustrations for various procedures.

The company has secured funding to support its growth, including a Series A round of up to $10 million in 2013, led by MVM Life Science Partners, with participation from Beteiligungsmanagement Thüringen. This investment was aimed at expanding R&D operations and global sales efforts. Over the years, eZono has achieved significant regulatory milestones, including CE registration and FDA 510(k) clearance for its devices, enabling sales in over 30 countries.